tirzepatide vs semaglutide review Comparative safety and side effects of and tirzepatide: Implications for clinical decision-making in obesity management Tirzepatide led to greater real-world

Cardiovascular outcomes trials (CVOTs) have shown that several GLP-1RAs, including semaglutide, reduced the relative risk of major adverse cardiovascular events (MACE) versus placebo in people with T2D and cardiovascular disease (CVD) or at high cardiovascular (CV) risk (non-inferiority for the risk of MACE with the OD oral formulation of semaglutide), without additional safety concerns [2,3,4,5,6]

doi:10.1186/s12958-018-0434-y

Authors relationships and activities JES has received honoraria for lectures and consultancies from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Pfizer

Current views on type 2 diabetes